Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
QLG2128 (abaloparatide injection) in postmenopausal osteoporosis at high fracture risk
CTR20251012Phase 3Active
- Sponsor
- Qilu Pharmaceutical
- Start
- Jun 2025
- Modality
- Peptides
- Countries
- 1
01
Overview
A Phase 3 trial of abaloparatide in osteoporosis, sponsored by Qilu Pharmaceutical. Started Jun 2025; status: active.
02
Drugs
abaloparatide
03
Conditions
osteoporosis
Beyond the preview
Go deeper on CTR20251012.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on CTR20251012.